Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical trial NCT06484062 · RECRUITING

Trial details

NCT number: NCT06484062
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome/Acute Myeloid Leukemia Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

Start date: 2025-08-15
Primary completion: 2028-06-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.